BUSINESS
Takeda’s Adcetris Gets European OK for 1st-Line Stage IV Hodgkin’s Lymphoma
Takeda Pharmaceutical said on February 11 that its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) earned an additional indication in Europe for its use in combination with adriamycin, vinblastine, and dacarbazine (AVD) in adult patients with previously untreated CD30-positive Stage IV…
To read the full story
Related Article
- Adcetris Label Expansion Gets European Panel Nod: Takeda
December 18, 2018
BUSINESS
- Kyowa Kirin to Drop Onglyza in First for Originator DPP-4 Inhibitors
November 18, 2026
- Towa, Sawai Grow Sales on Supply Gains; Biosimilars Emerge as New Focus for Others
November 18, 2026
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





